newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies